Xilio Therapeutics(us:XLO)
1.28
+36.46%
Updated on 2024-12-22
Open:1.06
Close:1.28
High:1.28
Low:0.8364
Pre Close:0.9380
Volume:6.83M
Amount:7.52M
Turnover:15.54%
Shares:43.96M
MarketCap:56.27M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 37 | 13034068 | 29.66% | 7 | 9 | 12 |
| 2024-03-31 | 37 | 10996048 | 31.90% | 6 | 5 | 12 |
| 2023-12-31 | 35 | 14951528 | 54.16% | 5 | 8 | 7 |
| 2023-09-30 | 33 | 15860410 | 57.61% | 1 | 5 | 10 |
| 2023-06-30 | 33 | 16002286 | 58.15% | 1 | 4 | 7 |
| 2023-03-31 | 32 | 16072057 | 58.57% | 4 | 6 | 3 |
| 2022-12-31 | 31 | 15926513 | 58.07% | 2 | 7 | 8 |
| 2022-09-30 | 35 | 16607116 | 60.59% | 3 | 3 | 15 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Bain Capital Life Sciences Investors, Llc | 2805413 | 8.14% | 0 | |
| 2024-03-31 | Fmr Llc | 1907671 | 5.53% | 0 | |
| 2024-03-31 | Rivervest Venture Management Llc | 1441444 | 4.18% | 0 | |
| 2024-03-31 | Rock Springs Capital Management Lp | 1440759 | 4.18% | 0 | |
| 2024-03-31 | Atlas Venture Life Science Advisors, Llc | 992912 | 2.88% | -1766432 | -64.02% |
| 2024-03-31 | Vanguard Group Inc | 902531 | 2.62% | 0 | |
| 2024-03-31 | Balyasny Asset Management L.P. | 338542 | 0.98% | 338542 | |
| 2024-03-31 | Renaissance Technologies Llc | 249446 | 0.72% | 39746 | 18.95% |
| 2024-03-31 | Morgan Stanley | 221905 | 0.64% | 94640 | 74.36% |
| 2024-03-31 | Fil Ltd | 218705 | 0.63% | 0 |
About
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Address:828 Winter Street,Suite 300
Website:http://www.xiliotx.com
Market Movers